Abstract:Human norovirus was discovered more than five decades ago and is a widespread cause of outbreaks of acute gastroenteritis. There are no approved vaccines or antivirals currently available. However, norovirus inhibitors, including capsid-specific monoclonal antibodies (Mabs) and nanobodies, have recently shown promising results. Several Mabs and nanobodies were found to inhibit norovirus replication using a human intestinal enteroid (HIE) culture system and/or could block norovirus attachment to histo-blood group antigen (HBGA) co-factors. In our pursuit to develop a single broad-spectrum norovirus therapeutic, we continued our analysis and development of a cross-reactive and HBGA interfering nanobody (NB26). To improve NB26 binding capacity and therapeutic potential, we conjugated NB26 onto a human IgG Fc domain (Fc-NB26). We confirmed that Fc-NB26 cross-reacts with genetically diverse GII genotype capsid protruding (P) domains (GII.8, GII.14, GII.17, GII.24, GII.26, and GII.NA1) using a direct enzyme-linked immunosorbent assay. Furthermore, X-ray crystallography structures of these P domains and structures of other GII genotypes reveal that the NB26 binding site is largely conserved, validating its broad reactivity. We showed that Fc-NB26 has ~100-fold higher affinity toward the norovirus P domain compared to native NB26. We also found that both NB26 and Fc-NB26 neutralize human norovirus replication in the HIE culture system. Furthermore, the mode of inhibition confirmed that like NB26, Fc-NB26 caused norovirus particle disassembly and aggregation. Overall, these new findings demonstrate that structural modifications to nanobodies can improve their therapeutic potential.IMPORTANCEDeveloping vaccines and antivirals against norovirus remains a challenge, mainly due to the constant genetic and antigenic evolution. Moreover, re-infection with genetically related and/or antigenic variants is not uncommon. We further developed our leading norovirus nanobody (NB26) that indirectly interfered with norovirus binding to HBGAs, by converting NB26 into a dimeric Fc-linked Nanobody (Fc-NB26). We found that Fc-NB26 had improved binding affinity and neutralization capacity compared with native NB26. Using X-ray crystallography, we showed this nanobody engaged highly conserved capsid residues among genetically diverse noroviruses. Development of such broadly reactive potent therapeutic nanobodies delivered as a slow-releasing prophylactic could be of exceptional value for norovirus outbreaks, especially for the prevention or treatment of severe acute gastroenteritis in high-risk groups such as the young, elderly, and immunocompromised.

Generation of Nucleic Acid Aptamer Candidates against a Novel Calicivirus Protein Target

Development and evaluation of a novel in situ target-capture approach for aptamer selection of human noroviruses

Ultrasensitive Norovirus Detection Using DNA Aptasensor Technology

Establishment and application of one-step multiplex real-time RT-PCR assay for the detection of human calicivirus

Characterization of a Norovirus-specific monoclonal antibody that exhibits wide spectrum binding activities

Bioinformatics analysis of the epitope regions for norovirus capsid protein

Sensitive Electrochemical and Thermal Detection of Human Noroviruses Using Molecularly Imprinted Polymer Nanoparticles Generated against a Viral Target

Characterization of Cross-Reactive Norovirus-Specific Monoclonal Antibodies

Characterization of a Novel Conformational GII.4 Norovirus Epitope: Implications for Norovirus-Host Interactions

A norovirus detection architecture based on isothermal amplification and expanded genetic systems

Biological and immunological characterization of norovirus major capsid proteins from three different genotypes

Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses

Identification of a norovirus GII-specific antigenic epitope

Structural analyses of the GI.4 norovirus by cryo-electron microscopy and X-ray crystallography revealing binding sites for human monoclonal antibodies

Identification of a GII.6 norovirus blockade antibody epitope

Biological and immunological characterization of major capsid protein VP1 from distinct GII.2 norovirus clusters

A universal primer-independent next-generation sequencing approach for investigations of norovirus outbreaks and novel variants

Sensitive detection of norovirus using phage nanoparticle reporters in lateral-flow assay

Characterization of cross-reactive, non-neutralizing monoclonal antibodies against a pandemic GII.4 norovirus variant

Development of a Nanobody-Based Lateral Flow Immunoassay for Detection of Human Norovirus